ENTOD Pharmaceuticals announces CDSCO approval of 0.05% atropine drops in India

The atropine sulphate ophthalmic solution 0.05% is pH-balanced and indicated for long-term, daily use by pediatric patients.

(Image credit: ©vitalis83 – stock.adobe.com)

Article was edited to include the correct study that supported the CDSCO approval on April 24, 2025 at 10:35 am EST.

Mumbai-based ENTOD Pharmaceuticals announced its 0.05% atropine eye drops (Myatro XL) have received marketing authorization from India's Central Drugs Standard Control Organization (CDSCO). The atropine eye drops are designed to slow myopia progression in children ages 6 to 12, the company said in a press release.¹

The 0.05% atropine drops will be available by prescription in India beginning in July 2025, ENTOD Pharmaceuticals said in a press release. Myatro XL joins ENTOD’s Myatro line.

The atropine sulphate ophthalmic solution 0.05% is pH-balanced and indicated for long-term, daily use by pediatric patients. In order to aid compliance and adherence, a dedicated MYATRO mobile app will become available in the Google Play and Apple App Store upon launch. The patient-centric app will provide bottle discard reminders, follow-up appointment reminders, and other means of secure monitoring for compliance with the MYATRO XL drops and other products in the MYATRO line. Currently, the MYATRO line includes 0.01% atropine drops; the lower-volume solution is available for patients aged 4 to 14 years with pediatric myopia.

Phase 3 study shows efficacy, safety of atropine 0.05%

The marketing authorization comes on the heels of successful completion of phase 3 studies in India.¹ Specifically, a multicenter, randomized, double-blinded, parallel group and comparative study supported the CDSCO approval. The study was conducted across 11 sites in India and included 190 children aged 6 to 12 years with a clinical diagnosis of myopia.² The primary end point of the study was the mean change in spherical equivalent refractive error from baseline to 12 months. The secondary end point measured the proportion of subjects showing less than 0.50 diopters (D) (spherical equivalent) of myopia progression compared to baseline. The first end point was measured by cycloplegic autorefraction, whereas the secondary end point was measured by cycloplegic autorefraction, and mean change in ocular axial length pupil size, change in accommodation amplitude, and visual acuity, all from baseline to 12 months.²

Study participants were split into 2 arms: 1 was administered atropine sulphate 0.05% and the other with atropine sulphate 0.01% at a dose of 1 drop once a day – preferably at night – in each eye for a period of 12 months.²

Study results showed a "significant difference" between the change in spherical equivalent refractive error between atropine sulphate 0.05% and 0.01% after 12 months of treatment, as observed in the right [-0.13±0.62 D vs -0.33±0.80 D] [P = .0493] and left eyes [ -0.15±0.71 D vs -0.34±0.88 D] according to the release. Atropine sulphate 0.05% was observed to have a better outcome in controlling myopia progression than atropine sulphate 0.01%.²

Additionally, atropine sulphate 0.05% showed a higher proportion of participants with less than 0.50 D myopia progression in comparison to atropine sulphate 0.01% in both the right eye (76.09% vs 65.56%) and left eye (71.74% vs 70.00%). Atropine sulphate 0.05% also showed a more significant difference in ocular axial length changes compared to atropine sulphate 0.01% after 12 months of treatment in both the right eye (0.04±0.68 mm vs 0.11±0.86 mm) and left eye (0.05±0.71 mm vs 0.10±0.91 mm).²

Atropine sulphate 0.05% was shown to be safe and well tolerated, with no serious adverse effects reported during the trial.²

References

1. ENTOD Pharmaceuticals receives DCGI approval for the world’s first 0.05% Atropine eye drops to slow down Myopia Progression in children. Press release. Entod Pharmaceuticals Ltd. Published April 22, 2025. Accessed April 23, 2025. https://cdn.qr-code-generator.com/account2645627/52642472_5.pdf?Expires=1745585114&Signature=B72NvN2fA~l4Spgn5j8twjYW7rrw-EfF-~m4AsTMMubZj5lqTvRKu7ahDgrrItCL3jTnl7kEZCUlas5Rd-5EBR~rR0UeWWYjvUTCGar-X3cBwnpajU8xls45xmS-zsIgh5kUmtl8a0dvM2k7i0RRZnvGTGDmH8-VyhJzeK17yhjiAnlrx2Oofx6ARc2TFOXdh-HVnZweqfLO7C4UYwHKSb15u2wXBj2IjSW2BJqACA0kTvcYM76~-mcVzFxwmkg4ctonVhMbhUqS4kE0AJM0u41s8CzFLTyKQlKE8qI~x2Nj8vMLSWtg5vthDaCJZsgOFPzNFdcwhXupmWpvW8Gyvw__&Key-Pair-Id=KKMPOJU8AYATR
2. Clinical Trial Registry of India. CTRI/2022/04/041667. Last updated May 23, 2024. Accessed April 24, 2025.